|

Effect of Honey For CIN II

RECRUITINGPhase 1/2Sponsored by Zuyderland Medisch Centrum
Actively Recruiting
PhasePhase 1/2
SponsorZuyderland Medisch Centrum
Started2024-12-30
Est. completion2026-12-01
Eligibility
Age18 Years – 40 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06219018

Summary

The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus and an increase in the normalization of CIN II lesions compared to expectant management.

Eligibility

Age: 18 Years – 40 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Women 18-40 years
* Primary CIN II confirmed histologically in the biopsy on colposcopic examination
* Sufficient mastery of the Dutch language

Exclusion Criteria:

* Simultaneous abnormality in columnar epithelial cells (AIS).
* Hr-HPV negative cytology
* Immunosuppressant use/Autoimmune disease (HIV, CVID)
* History of cervical carcinoma or previous treatment for CIN (LLETZ or imiquimod)
* Pregnancy or the intention to become pregnant during the study period
* Legal incompetence
* Known allergies to honey

Conditions3

CancerCervical Intraepithelial Neoplasia-IIHigh Risk Human Papillomavirus

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.